Brokerages Set ABIOMED, Inc. (ABMD) Target Price at $150.83

ABIOMED, Inc. (NASDAQ:ABMD) has been given a consensus rating of “Buy” by the seven analysts that are presently covering the firm. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $152.00.

A number of analysts have weighed in on the stock. Leerink Swann increased their target price on shares of ABIOMED from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, March 30th. Piper Jaffray Companies raised shares of ABIOMED from a “neutral” rating to an “overweight” rating and set a $145.00 target price on the stock in a report on Thursday, April 6th. TheStreet raised shares of ABIOMED from a “c+” rating to a “b-” rating in a report on Tuesday, February 21st. Zacks Investment Research cut shares of ABIOMED from a “hold” rating to a “sell” rating in a report on Thursday, January 5th. Finally, BTIG Research reissued a “buy” rating and set a $170.00 target price on shares of ABIOMED in a report on Sunday, January 8th.

WARNING: This report was originally posted by sleekmoney and is owned by of sleekmoney. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at http://sleekmoney.com/brokerages-set-abiomed-inc-abmd-target-price-at-150-83/1739236.html.

In other ABIOMED news, VP Andrew J. Greenfield sold 10,000 shares of the stock in a transaction on Friday, March 17th. The shares were sold at an average price of $124.00, for a total transaction of $1,240,000.00. Following the sale, the vice president now directly owns 66,307 shares of the company’s stock, valued at $8,222,068. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in ABMD. Capstone Asset Management Co. raised its position in ABIOMED by 2.8% in the first quarter. Capstone Asset Management Co. now owns 6,340 shares of the company’s stock valued at $794,000 after buying an additional 170 shares in the last quarter. Bank of Montreal Can raised its position in ABIOMED by 48.7% in the first quarter. Bank of Montreal Can now owns 19,902 shares of the company’s stock valued at $2,492,000 after buying an additional 6,520 shares in the last quarter. Creative Planning raised its position in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the company’s stock valued at $115,000 after buying an additional 129 shares in the last quarter. Teachers Advisors LLC raised its position in ABIOMED by 6.5% in the fourth quarter. Teachers Advisors LLC now owns 42,452 shares of the company’s stock valued at $4,783,000 after buying an additional 2,608 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in ABIOMED during the fourth quarter valued at approximately $486,000. Institutional investors and hedge funds own 92.67% of the company’s stock.

Shares of ABIOMED (NASDAQ:ABMD) traded down 0.31% during mid-day trading on Monday, hitting $125.09. 81,235 shares of the company traded hands. The firm has a 50-day moving average price of $122.38 and a 200 day moving average price of $116.87. The firm has a market cap of $5.43 billion, a price-to-earnings ratio of 117.02 and a beta of 0.51. ABIOMED has a 52-week low of $92.03 and a 52-week high of $132.95.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, January 26th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.05. The firm had revenue of $114.70 million for the quarter, compared to analysts’ expectations of $112.71 million. ABIOMED had a net margin of 11.63% and a return on equity of 12.35%. The firm’s quarterly revenue was up 33.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 earnings per share. Equities research analysts anticipate that ABIOMED will post $1.18 EPS for the current fiscal year.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

5 Day Chart for NASDAQ:ABMD

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/brokerages-set-abiomed-inc-abmd-target-price-at-150-83/1739236.html

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *